• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Aidoc Receives FDA Permission for COVID-19 AI Detection Tool


Tool pinpoints incidental findings on CT scans that contain the lung or part of the lung.

Artificial intelligence (AI) radiology solution company Aidoc announced Friday it has received permission from the U.S. Food & Drug Administration (FDA) for its tool designed for the detection of COVID-19 findings.

According to a company statement, the tool detects and prioritizes incidental CT findings, such as ground-glass opacities, in any scans that contain the lung or part of the lungs, including chest, abdomen, and cervical spine. Pinpointing these findings can provide additional information that can, potentially, augment patient evaluation.

The tool is the most recent addition to Aidoc’s AI tools that detect intracranial hemorrhage, large-vessel occlusion, pulmonary embolism in pulmonary angiography, and cervical spine features.

“In our experience, it is not unusual for the radiologist to be the first to diagnose COVID-19 disease in patients especially when the disease is clinically unsuspected. The outbreak of the COVID-19 pandemic may occur in waves and should these waves occur, it will become increasingly important to identify imaging findings suggestive of COVID-19 in a variety of clinical settings,” said Paul Chang, M.D. professor of radiology and vice chair of radiology informatics at the University of Chicago Medicine. “Aidoc’s ability to detect and triage patients with incidental findings associated with COVID-19 acts as another layer of protection as the disease may continue to circulate in the months to come.”

Based on studies from universities in Brussels, Chicago, Brescia, and Maimonides Medical Center in New York, radiologists reviewing CT scans for other reasons, such as oncology or abdominal pain screenings, discovered that 8 percent-to-10 percent of patients were also COVID-19-positive. These patients had not shown any other COVID-19-associated respiratory symptoms.

The goal, company officials said, is for the tool to create a safety net that can help radiologists identify and address potentially life-threatening conditions as they work through the anticipated backlog of imaging studies created by the pandemic.

Related Videos
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Nina Kottler, MD, MS
The Executive Order on AI: Promising Development for Radiology or ‘HIPAA for AI’?
Practical Insights on CT and MRI Neuroimaging and Reporting for Stroke Patients
Related Content
© 2024 MJH Life Sciences

All rights reserved.